| Literature DB >> 26471342 |
Kun-Chia Chang1,2, Chung-Ying Lin3.
Abstract
BACKGROUND: Methadone maintenance treatment programs (MMTPs) are important public health intervention to control the human immunodeficiency virus (HIV) and the drug use problems. For expanding treatment coverage, publicly funded programs may be necessary for heroin users with low socio-economic status. We evaluated the difference of demographics, clinical features, and quality of life (QoL) of heroin users enrolled in publicly funded and self-paid MMTP and explored determinants influencing their attendance rate, respectively, for these two groups.Entities:
Mesh:
Substances:
Year: 2015 PMID: 26471342 PMCID: PMC4608217 DOI: 10.1186/s12954-015-0076-8
Source DB: PubMed Journal: Harm Reduct J ISSN: 1477-7517
The baseline characteristics and QoL scores comparisons using independent t tests (for continuous variables) or χ 2 tests (for categorical variables) between publicly funded and self-paid methadone maintenance treatment patients
| Publicly funded | Self-paid |
|
| |||
|---|---|---|---|---|---|---|
|
| Mean (SD) |
| Mean (SD) | |||
| Age (year) | 129 | 38.29 (7.65) | 105 | 37.97 (7.16) | 0.32 | 0.747 |
| Gender | 0.93 | 0.334 | ||||
| Female | 11 | 13 | ||||
| Male | 118 | 92 | ||||
| Living alonea | 1.99 | 0.158 | ||||
| No | 118 | 98 | ||||
| Yes | 11 | 4 | ||||
| Educational years | 129 | 9.36 (2.55) | 105 | 9.48 (2.09) | 0.40 | 0.688 |
| Age of first heroin use | 129 | 25.59 (5.89) | 105 | 26.92 (6.80) | 1.65 | 0.101 |
| Heroin using yearsa | 112 | 9.25 (6.77) | 82 | 6.48 (3.86) | 3.59 | <0.001 |
| Fixed employmenta | <0.01 | 0.975 | ||||
| No | 60 | 49 | ||||
| Yes | 68 | 56 | ||||
| Family drug using | 0.47 | 0.495 | ||||
| No | 109 | 92 | ||||
| Yes | 20 | 13 | ||||
| HBV carrier | 0.28 | 0.597 | ||||
| Seronegative | 106 | 89 | ||||
| Seropositive | 23 | 16 | ||||
| HCV carrier | 3.30 | 0.069 | ||||
| Seronegative | 4 | 9 | ||||
| Seropositive | 125 | 96 | ||||
| HIV carrier | 45.35 | <0.001 | ||||
| Seronegative | 84 | 105 | ||||
| Seropositive | 45 | 0 | ||||
| Physical QoLa | 128 | 11.95 (1.89) | 103 | 12.48 (1.94) | 2.10 | 0.036 |
| Psychological QoL | 129 | 11.94 (2.68) | 105 | 12.83 (2.12) | 2.83 | 0.005 |
| Social QoLa | 129 | 12.62 (3.12) | 104 | 13.44 (2.80) | 2.09 | 0.038 |
| Environment QoL | 129 | 12.47 (2.86) | 105 | 13.43 (2.30) | 2.77 | 0.006 |
QoL quality of life, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus
aWith missing values
Comparisons using one-sample t tests between methadone maintenance treatment patients and Taiwan population
| Publicly funded | Self-paid | ||
|---|---|---|---|
| Physical QoL |
| 128 | 103 |
| Mean (SD) | 11.95 (1.89) | 12.48 (1.94) | |
|
| −12.66 (<0.001)a | −8.25 (<0.001)a | |
| Psychological QoL |
| 129 | 105 |
| Mean (SD) | 11.94 (2.68) | 12.83 (2.12) | |
|
| −5.45 (<0.001)b | −1.93 (0.056)b | |
| Social QoL |
| 129 | 104 |
| Mean (SD) | 12.62 (3.12) | 13.44 (2.80) | |
|
| −3.42 (0.001)c | −0.43 (0.669)c | |
| Environment QoL |
| 129 | 105 |
| Mean (SD) | 12.47 (2.86) | 13.43 (2.30) | |
|
| −0.98 (0.327)d | 3.15 (0.002)d |
aCompare with Taiwan population (mean ± SD = 14.06 ± 2.34)
bCompare with Taiwan population (mean ± SD = 13.23 ± 2.15)
cCompare with Taiwan population (mean ± SD = 13.56 ± 2.29)
dCompare with Taiwan population (mean ± SD = 12.72 ± 2.07)
Predictors of attendance rate on the heroin-dependent individuals receiving methadone maintenance treatment using generalized estimating equation models
| Attendance rate (3, 6, 9, 12, 15, and 18 months) | ||||
|---|---|---|---|---|
| Publicly funded | Self-paid | |||
|
| (95 % CI) |
| (95 % CI) | |
| Age (year) | 0.005 | (−0.001, 0.010) | 0.001 | (−0.004, 0.006) |
| Gender (ref: female) | −0.115* | (−0.216, −0.013) | −0.017 | (−0.101, 0.066) |
| Living alone (ref: no) | 0.088** | (0.024, 0.152) | 0.023 | (−0.111, 0.156) |
| Educational years | −0.005 | (−0.001, 0.010) | −0.013 | (−0.026, <0.001) |
| Age of first heroin use | −0.007* | (−0.012, −0.001) | <0.001 | (−0.006, 0.005) |
| Fixed employment (ref: no) | −0.002 | (−0.055, 0.051) | 0.053 | (−0.004, 0.111) |
| Family drug using (ref: no) | 0.046 | (−0.016, 0.107) | 0.026 | (−0.074, 0.125) |
| HBV (ref: seronegative) | −0.015 | (−0.093, 0.063) | 0.026 | (−0.062, 0.113) |
| HCV (ref: seronegative) | −0.068* | (−0.120, −0.016) | 0.224** | (0.085, 0.363) |
| HIV (ref: seronegative) | 0.009 | (−0.051, 0.069) | –a | –a |
| Physical QoL | −0.015 | (−0.034, 0.004) | 0.022 | (−0.001, 0.045) |
| Psychological QoL | −0.010 | (−0.025, 0.006) | −0.011 | (−0.031, 0.009) |
| Social QoL | −0.002 | (−0.017, 0.013) | −0.020* | (−0.034, −0.006) |
| Environment QoL | 0.012 | (−0.003, 0.028) | 0.019 | (−0.001, 0.039) |
QoL quality of life, HBV hepatitis B virus, HCV hepatitis C virus, HIV human immunodeficiency virus
*P < 0.05, **P < 0.01, ***P < 0.001
aNo values due to no HIV patients in this model